Literature DB >> 2470780

Interferon-beta impairs induction of HLA-DR antigen expression in cultured adult human astrocytes.

B P Barna1, S M Chou, B Jacobs, B Yen-Lieberman, R M Ransohoff.   

Abstract

We studied the effect of interferons on the expression of class II histocompatibility (HLA-DR) antigens by cultured adult human astrocytes. Cultures were derived from brain tissue resected for surgical treatment of intractable epilepsy. Cultured astrocytes did not spontaneously display HLA-DR antigen as determined by immunocytochemistry and flow cytometry with antibody to HLA-DR. Astrocytes cultured for 72 h with recombinant or natural interferon-gamma (IFN gamma) demonstrated a dose-dependent increase in HLA-DR expression with optimal stimulation by 100 U/ml IFN gamma. HLA-DR expression was not detectable in astrocytes cultured with IFN gamma for less then 48 h, and peak HLA-DR expression (over 80% of cells) was seen at 120 h of culture. Optimal HLA-DR expression required continuous presence of IFN gamma. Exposure of astrocytes to recombinant or natural interferon-beta (IFN beta) did not induce HLA-DR and pretreatment of astrocytes with IFN beta or interferon-alpha (IFN alpha) significantly inhibited subsequent induction of HLA-DR expression by IFN gamma. These observations suggest that interferons may function in regulating human astrocyte HLA-DR expression within the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2470780     DOI: 10.1016/0165-5728(89)90072-6

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  13 in total

Review 1.  First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.

Authors:  Jessica Johnston; Tsz-Yin So
Journal:  Drugs       Date:  2012-06-18       Impact factor: 9.546

2.  Therapeutic action of cannabinoids in a murine model of multiple sclerosis.

Authors:  Angel Arévalo-Martín; José Miguel Vela; Eduardo Molina-Holgado; José Borrell; Carmen Guaza
Journal:  J Neurosci       Date:  2003-04-01       Impact factor: 6.167

3.  Intrathecal application of interferon gamma. Progressive appearance of MHC antigens within the rat nervous system.

Authors:  K Vass; H Lassmann
Journal:  Am J Pathol       Date:  1990-10       Impact factor: 4.307

Review 4.  Interferons in relapsing-remitting multiple sclerosis: are there benefits from long-term use?

Authors:  Oscar Fernández
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

5.  Combination therapy with a synthetic peptide of C-reactive protein and interleukin 2: augmented survival and eradication of pulmonary metastases.

Authors:  B P Barna; M J Thomassen; M Maier; S V Medendorp; R R Tubbs; T Chiang; P Zhou; B Yen-Lieberman; S Singh-Burgess; S D Deodhar
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

6.  Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma.

Authors:  H T Lu; J L Riley; G T Babcock; M Huston; G R Stark; J M Boss; R M Ransohoff
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

7.  Interleukin-4 down-regulates adult human astrocyte DNA synthesis and proliferation.

Authors:  M L Estes; K Iwasaki; B S Jacobs; B P Barna
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

Review 8.  Interferons in multiple sclerosis. A review of the evidence.

Authors:  H S Panitch
Journal:  Drugs       Date:  1992-12       Impact factor: 9.546

Review 9.  Autoimmune disease and the nervous system. Biochemical, molecular, and clinical update.

Authors:  J E Merrill; M C Graves; D G Mulder
Journal:  West J Med       Date:  1992-06

Review 10.  Adaptive immune responses in CNS autoimmune disease: mechanisms and therapeutic opportunities.

Authors:  Rhoanne C McPherson; Stephen M Anderton
Journal:  J Neuroimmune Pharmacol       Date:  2013-04-09       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.